<i>TP53</i> status and impact on AML prognosis within the ELN 2022 risk classification
Shaun Fleming, Xavier Cheng-Hong Tsai, Rhiannon Morris, Hsin‐An Hou, Andrew H. Wei
Abstract
This study reports the following: (1) frequency of TP53 comutation within each component of the European LeukemiaNet 2022 acute myeloid leukemia risk classification, (2) relevance of TP53 mutated variant allelic fraction <10%, (3) prognostic impact of -7, -5/del(5q), -17/abn(17p), complex karyotype/monosomal karyotype, or myelodysplasia-related gene mutations with/without mutated TP53.
Topics & Concepts
MedicineMyeloid leukemiaOncologyInternal medicineKaryotypeLeukemiaMyeloidGeneGeneticsBiologyChromosomeAcute Myeloid Leukemia ResearchMultiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics